3,609 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Acquired by Empirical Asset Management LLC

Empirical Asset Management LLC purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,609 shares of the medical equipment provider's stock, valued at approximately $323,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the third quarter valued at $25,000. Signaturefd LLC lifted its holdings in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares during the last quarter. UMB Bank n.a. boosted its position in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after buying an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in Lantheus in the third quarter valued at about $51,000. Finally, GAMMA Investing LLC grew its stake in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after buying an additional 146 shares during the last quarter. Institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LNTH. JMP Securities reiterated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, Truist Financial reaffirmed a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Lantheus has a consensus rating of "Moderate Buy" and a consensus price target of $131.86.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $0.11 during midday trading on Friday, hitting $91.47. The stock had a trading volume of 585,496 shares, compared to its average volume of 743,446. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm has a market cap of $6.36 billion, a P/E ratio of 15.22 and a beta of 0.46. The company's 50-day simple moving average is $89.72 and its 200 day simple moving average is $100.14.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.10% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.